Kenvue Inc. (NYSE:KVUE) Shares Sold by Yacktman Asset Management LP

Yacktman Asset Management LP lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 8,306,672 shares of the company’s stock after selling 74,732 shares during the quarter. Kenvue comprises about 2.1% of Yacktman Asset Management LP’s portfolio, making the stock its 19th largest position. Yacktman Asset Management LP’s holdings in Kenvue were worth $177,347,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Huntington National Bank lifted its position in Kenvue by 26.5% during the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after purchasing an additional 871 shares during the period. ING Groep NV lifted its holdings in shares of Kenvue by 23.6% in the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after buying an additional 681,954 shares during the period. Everence Capital Management Inc. boosted its stake in shares of Kenvue by 122.1% in the fourth quarter. Everence Capital Management Inc. now owns 45,380 shares of the company’s stock worth $969,000 after buying an additional 24,950 shares during the last quarter. Tyler Stone Wealth Management grew its holdings in Kenvue by 134.4% during the third quarter. Tyler Stone Wealth Management now owns 49,050 shares of the company’s stock worth $1,135,000 after acquiring an additional 28,125 shares during the period. Finally, Saturna Capital Corp raised its position in Kenvue by 29.9% during the third quarter. Saturna Capital Corp now owns 1,334,860 shares of the company’s stock valued at $30,875,000 after acquiring an additional 307,039 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

KVUE has been the topic of several recent research reports. Barclays lowered their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Canaccord Genuity Group cut their price objective on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a report on Friday. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $23.00.

Kenvue Price Performance

NYSE:KVUE opened at $20.60 on Tuesday. The firm has a market cap of $39.49 billion, a P/E ratio of 38.86, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The stock has a 50 day moving average of $21.54 and a two-hundred day moving average of $22.00. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts expect that Kenvue Inc. will post 1.05 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.98%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.